Evidence map›Paper›PMID 42941529›Full record

ArticleJournal of clinical medicine2026

Semaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience.

Ilaria Proietti, Concetta Potenza

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ilaria ProiettiUOC DERMATOLOGIA 'Daniele Innocenzi'-ASL LATINA Sapienza Università di Roma-Polo Pontino, Corso della Repubblica, 79, 04100 Latina, Italy.
Concetta PotenzaUOC DERMATOLOGIA 'Daniele Innocenzi'-ASL LATINA Sapienza Università di Roma-Polo Pontino, Corso della Repubblica, 79, 04100 Latina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is often associated with obesity and type 2 diabetes mellitus (T2DM) due to a common low-grade chronic inflammatory mechanism amplified by metabolic dysfunction. Biologics have revolutionized psoriasis treatment, but patients with obesity show reduced responses and higher discontinuation rates. Glucagon-like peptide-1 receptor agonists-such as semaglutide-may enhance the efficacy of psoriasis care; however, data are limited in this context. We presented a retrospective analysis of our single-center real-world experience with 33 obese patients (24 men and 9 women) affected by mild (

Indexed as

obesitypsoriasisreal-world datasemaglutidetype 2 diabetes mellitus

Identifiers

PMID42941529
PMCPMC13705784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.